Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Construction in Progress (2017 - 2023)

CytomX Therapeutics (CTMX) has disclosed Construction in Progress for 7 consecutive years, with $368000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Construction in Progress fell 47.8% year-over-year to $368000.0, compared with a TTM value of $368000.0 through Dec 2023, down 47.8%, and an annual FY2023 reading of $368000.0, down 47.8% over the prior year.
  • Construction in Progress was $368000.0 for Q4 2023 at CytomX Therapeutics, down from $705000.0 in the prior quarter.
  • Across five years, Construction in Progress topped out at $705000.0 in Q4 2022 and bottomed at $236000.0 in Q4 2019.
  • Average Construction in Progress over 5 years is $373800.0, with a median of $308000.0 recorded in 2021.
  • The sharpest move saw Construction in Progress crashed 69.94% in 2019, then soared 128.9% in 2022.
  • Year by year, Construction in Progress stood at $236000.0 in 2019, then grew by 6.78% to $252000.0 in 2020, then increased by 22.22% to $308000.0 in 2021, then skyrocketed by 128.9% to $705000.0 in 2022, then tumbled by 47.8% to $368000.0 in 2023.
  • Business Quant data shows Construction in Progress for CTMX at $368000.0 in Q4 2023, $705000.0 in Q4 2022, and $308000.0 in Q4 2021.